Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Equity Average (2018 - 2025)

Historic Equity Average for Sutro Biopharma (STRO) over the last 8 years, with Q3 2025 value amounting to -$59.7 million.

  • Sutro Biopharma's Equity Average fell 14532.3% to -$59.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$59.7 million, marking a year-over-year decrease of 14532.3%. This contributed to the annual value of $97.1 million for FY2024, which is 4702.71% down from last year.
  • Latest data reveals that Sutro Biopharma reported Equity Average of -$59.7 million as of Q3 2025, which was down 14532.3% from -$29.0 million recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's Equity Average registered a high of $319.7 million during Q1 2021, and its lowest value of -$59.7 million during Q3 2025.
  • Its 5-year average for Equity Average is $163.2 million, with a median of $170.1 million in 2023.
  • Per our database at Business Quant, Sutro Biopharma's Equity Average soared by 25546.33% in 2021 and then plummeted by 14532.3% in 2025.
  • Quarter analysis of 5 years shows Sutro Biopharma's Equity Average stood at $268.1 million in 2021, then dropped by 16.67% to $223.4 million in 2022, then plummeted by 41.34% to $131.0 million in 2023, then crashed by 40.54% to $77.9 million in 2024, then crashed by 176.61% to -$59.7 million in 2025.
  • Its last three reported values are -$59.7 million in Q3 2025, -$29.0 million for Q2 2025, and $9.4 million during Q1 2025.